TNF-α treatment of valvular interstitial cell profibrotic activated myofibroblasts leads to increased calcification, potentially mediated by the MAPK/ERK signaling cascade.
TNF-α promotes calcification in profibrotic activated valvular myofibroblasts via the MAPK/ERK pathway, identifying a potential pharmaceutical target for aortic valve disease.
Pro-inflammatory cytokines play critical roles in regulating valvular interstitial cell (VIC) phenotypic changes that can cause heart valve fibrosis and calcification. Tumor necrosis factor alpha (TNF-α) is a cytokine known to influence VIC behavior and has been reported at high levels in calcified valves ex vivo. We sought to understand the specific effects of TNF-α on VIC phenotypes (eg, fibroblast, profibrotic activated myofibroblasts) and its link with heart valve disorders. We characterize human aortic valve tissue from patients with valve disorders and identify a high variability of fibrotic and calcific markers between tissues. These results motivated in vitro studies to explore the effects of TNF-α on defined VIC fibroblasts and profibrotic activated myofibroblasts, induced via FGF-2 and TGF-β1 treatment. Using 3D hydrogels to culture VICs, we measure the effect of TNF-α (0.1-10 ng/mL) on key markers of fibrosis (eg, αSMA, COL1A1) and calcification (eg, RUNX2, BMP2, and calcium deposits). We observe calcification in TNF-α-treated VIC activated myofibroblasts and identify the MAPK/ERK signaling cascade as a potential pathway for TNF-α mediated calcification. Conversely, VIC fibroblasts respond to TNF-α with decreased calcification. Treatment of VIC profibrotic activated myofibroblast populations with TNF-α leads to increased calcification. Our in vitro findings correlate with findings in diseased human valves and highlight the importance of understanding the effect of cytokines and signaling pathways on specific VIC phenotypes. Finally, we reveal MAPK/ERK as a potential pathway involved in VIC-mediated matrix calcification with TNF-α treatment, suggesting this pathway as a potential pharmaceutical target for aortic valve disease.
Rodriguez et al. (Sun,) conducted a other in Aortic valve disease. TNF-α was evaluated on Calcification and fibrotic markers (e.g., αSMA, COL1A1, RUNX2, BMP2, and calcium deposits). TNF-α treatment of valvular interstitial cell profibrotic activated myofibroblasts leads to increased calcification, potentially mediated by the MAPK/ERK signaling cascade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: